Germany · Delayed Price · Currency is EUR Biomark Diagnostics Statistics
Total Valuation
FRA:20B has a market cap or net worth of EUR 30.45 million. The enterprise value is 30.71 million.
| Market Cap | 30.45M |
| Enterprise Value | 30.71M |
Important Dates
The next estimated earnings date is Friday, August 28, 2026.
| Earnings Date | Aug 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
FRA:20B has 106.48 million shares outstanding. The number of shares has increased by 15.58% in one year.
| Current Share Class | 106.48M |
| Shares Outstanding | 106.48M |
| Shares Change (YoY) | +15.58% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 12.44% |
| Owned by Institutions (%) | n/a |
| Float | 48.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 819.81 |
| PB Ratio | 148.05 |
| P/TBV Ratio | 148.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.99, with a Debt / Equity ratio of 4.29.
| Current Ratio | 0.99 |
| Quick Ratio | 0.97 |
| Debt / Equity | 4.29 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.30 |
| Interest Coverage | -27.20 |
Financial Efficiency
Return on equity (ROE) is -142.59% and return on invested capital (ROIC) is -46.66%.
| Return on Equity (ROE) | -142.59% |
| Return on Assets (ROA) | -43.06% |
| Return on Invested Capital (ROIC) | -46.66% |
| Return on Capital Employed (ROCE) | -225.65% |
| Weighted Average Cost of Capital (WACC) | 2.56% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +48.96% in the last 52 weeks. The beta is -0.31, so FRA:20B's price volatility has been lower than the market average.
| Beta (5Y) | -0.31 |
| 52-Week Price Change | +48.96% |
| 50-Day Moving Average | 0.32 |
| 200-Day Moving Average | 0.31 |
| Relative Strength Index (RSI) | 32.96 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:20B had revenue of EUR 37,148 and -917,836 in losses. Loss per share was -0.01.
| Revenue | 37,148 |
| Gross Profit | 37,148 |
| Operating Income | -1.07M |
| Pretax Income | -917,836 |
| Net Income | -917,836 |
| EBITDA | -1.06M |
| EBIT | -1.07M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 628,115 in cash and 882,554 in debt, with a net cash position of -254,439 or -0.00 per share.
| Cash & Cash Equivalents | 628,115 |
| Total Debt | 882,554 |
| Net Cash | -254,439 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | 205,702 |
| Book Value Per Share | 0.00 |
| Working Capital | -8,645 |
Cash Flow
In the last 12 months, operating cash flow was -676,506 and capital expenditures -2,631, giving a free cash flow of -679,137.
| Operating Cash Flow | -676,506 |
| Capital Expenditures | -2,631 |
| Depreciation & Amortization | 10,109 |
| Net Borrowing | -248,841 |
| Free Cash Flow | -679,137 |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -2,877.95% |
| Pretax Margin | -2,470.75% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:20B does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.58% |
| Shareholder Yield | -15.58% |
| Earnings Yield | -3.01% |
| FCF Yield | -2.23% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:20B has an Altman Z-Score of -1.4 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.4 |
| Piotroski F-Score | 1 |